Chargement en cours...
The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
BACKGROUND: Hypomethylating agents (HMAs), such as decitabine (DAC), are currently used as first-line therapy for patients with high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) not eligible for standard chemotherapies. Exacerbation of thrombocytopenia is one of the prev...
Enregistré dans:
| Publié dans: | Cancer Manag Res |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735651/ https://ncbi.nlm.nih.gov/pubmed/31564981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S213931 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|